This site is intended for healthcare
professionals in Belgium and Luxembourg.
Select a Condition
RESOURCES
Reblozyl® reimbursement conditions (French)
Reblozyl® reimbursement conditions (Dutch)
Reconstitution Guide (French)
Reconstitution Guide (Dutch)
Administration Guide (French)
Administration Guide (Dutch)
MEDLIST Study video (MDS)
BELIEVE Study video
(B-thal)
Summary report of the Reblozyl® Scientific event March 2021
Summary report of "Reblozyl®: From theory to practice" June 2021
June 3rd 2021: From theory to practice, by Dr Platzbecker
June 3rd 2021: How to identify patients to put on Reblozyl® in Belgium? by Dr Meers (MDS)
June 3rd 2021: Reblozyl® in β-Thalassemia – Pathophysiology, Clinical data and clinical cases, by Pr Cappellini
March 2nd 2021: Transfusion in MDS: a heavy burden? by Dr. Langemeijer
March 2nd 2021: Ineffective erythropoiesis: understanding the biology, optimizing clinical practice by Pr Giagounidis (MDS)
March 2nd 2021: Which patients are candidates for treatment with luspatercept ? by Dr Selleslag (MDS)
March 2nd 2021: Ongoing clinical trials, by Pr Beckers (MDS)
Video interview (MDS): Dr Meers
Video interview (β-Thalassemia): Dr Colard
Video interview (MDS): Dr Dominik Selleslag – Unmet medical need
Video interview (MDS): Dr Marielle Beckers – Unmet medical need
Video interview (MDS): Dr Dominik Selleslag – Which patients for Reblozyl®?
Video interview (MDS): Dr Marielle Beckers – Which patients for Reblozyl®?
Should you wish to know more about mechanisms involved in erythropoiesis, impact of chronic anemia and burden of transfusions in hematologic disease, or listen to your peers about how they treat their patients, please visit: https://keepmaturationtrack.be
For further information please Contact Us.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Before prescribing Reblozyl®, please refer to the SmPC. View the EU SmPC in French, SmPC in Dutch.
